[2]Zeng H, Ran X, An L, et al. Disparities in stage at diagnosis for ffve common cancers in China: a multicentre, hospital-based, observational study. Lancet Public Health 2021;6:e877-87. [3]Ryska A, Berzinec ...
参考文献: [1]Zeng H, Ran X, An L, et al. Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study[J]. The Lancet Public Health, 2021, 6(12): e877-e887. [2]Zhou C, Wang Z, Sun Y, et al. Sugemalimab versus placebo...
Complete your NSCLC diagnosis and learn more about how biomarker testing can help you and your doctor develop a comprehensive treatment plan.
PCN12 STAGE DISTRIBUTION AT DIAGNOSIS OF NON-SMALL CELL LUNG CANCER (NSCLC) AND GEOGRAPHIC VARIATION IN SURVIVALdoi:10.1016/j.jval.2019.04.136S. ChikermaneM.L. JohnsonElsevier BVValue in Health
There’s one more step to complete your diagnosis. Choose your NSCLC stage below to explore your next step. I have been diagnosed withEARLY STAGE (RESECTABLE) NSCLC LEARN MORE I have been diagnosed withSTAGE IV (METASTATIC) NSCLC LEARN MORE ...
(adjusted HR [AHR], 1.43; 95% CI, 1.41-1.45), between 4 and 6 months (AHR, 1.39; 95% CI, 1.37-1.41), and between 7 and 12 months (AHR, 1.17; 95% CI, 1.15-1.19) after discharge from the hospital following stage I to III NSCLC resection had worse overall survival than une...
[4]Villano JL, et al. Incidence of brain metastasis at initial presentation of lung cancer. Neuro Oncol. 2015 Jan;17(1):122-8. [5]Patil T, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-...
JL, et al. Association of molecular status and metastatic organs at diagnosis in patients with stage IV non﹒uamous non﹎all cell lung cancer. Lung Cancer.2018;121:76 1.[4] Dormieux A, Mezquita L, Cournede PH, et al. Association of metastatic pattern and molecular status in stage IV ...
The country-specific distributions of NSCLC stage at diagnosis were derived from a large observational, prospective cohort study on disease characteristics, treatment patterns, and outcomes related to treatment in select European countries (EPICLIN). Country-specific estimates of the second and third LOT...
(NSCLC),and two-thirds of which has aIready been in adVanced stage at diagnosis. Combined—moda¨ty treatment with surge哏阳diothe曙py’and chemothe陷py ls the maln measure for the the陀py 0f NSCLC,but the 5一year 0Ve陋¨surviVaI陌te iS st-¨ Iess than 15%.PIatinum—based ChemO...